Neuron-specific Humoral and Cellular Immune Correlates of Structural and Functional Brain Connectomics in Neuropsychiatric Lupus (INLES)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Milano, Italy
- Recruiting
- IRCCS Ospedale San Raffaele
-
Contact:
- NA NA
- Phone Number: 0226437912
- Email: ctc.trialstartup@hsr.it
-
Principal Investigator:
- Giuseppe A. Ramirez, MD, PhD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
Patients with SLE
- Diagnosis of SLE according to the ACR 1997, SLICC 2012 or EULAR/ACR 2019 criteria
- age ≥ 18 years (reference centre)
- age 15-17 years (affiliated centre)
Healthy subjects
- Charlson's Comorbidity Index=0 and no chronic treatment
- age ≥ 18 years (reference centre)
- age 15-17 years (affiliated centre)
Exclusion Criteria:
- History of T-cell neoplasia
- Active B-cell neoplasia or history of B-cell neoplasia of less than five years
- Contraindications to MRI
- Pregnancy
- Ongoing or past treatment with T-depleting agents
- History of brain cancer
- History of congenital brain disorders
- Cerebral disorders secondary to trauma, toxins or other metabolic or environmental factors unrelated to SLE according to the Investigator's evaluation
- Any other condition conferring excessive physical and psychological risk to the subject according to the Investigator's opinion
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
systemic lupus erythematosus
Patients with SLE according to the 1997 ACR, 2012 SLICC or 2019 EULAR/ACR criteria will undergo MRI along with neuropsychological tests, rheumatological evaluation and blood sample collection at baseline and after at least 12 months or during a new neuropsychiatric manifestation.
In case of existing MRI with compatible features, they will be used as baseline studies.
|
brain MRI
|
|
healthy controls
Subjects with Charlson's Comorbidity Index=0 with no ongoing chronic therapy and no history of immune-mediated disease will undergo a single MRI study, along with neuropsychological tests and blood sample collection.
In case of existing MRI with compatible features, no additional studies will be performed in this cohort.
|
brain MRI
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
To detect regional brain functional abnormalities in patients with SLE through advanced magnetic resonance imaging (MRI).
Time Frame: 12 months (extensions allowed for existing images before study onset)
|
All study subjects will be assessed at baseline through 3T MRI.
Repeat MRI will be performed after at least 12 months or in case of new neuropsychiatric events in all patients with SLE.
The MRI protocol will include conventional structural sequences (3D fluid-attenuated inversion recovery [FLAIR], 3D T1-weighted inversion recovery prepared gradient echo), advanced structural sequences (diffusion-weighted [DW] pulsed-gradient spin-echo [PSGE] single-shot echo-planar imaging, optimized for an accurate estimation of the neuriteorientation dispersion and density imaging [NODDI] model), and functional MRI sequences acquired in resting-state condition.
|
12 months (extensions allowed for existing images before study onset)
|
|
To identify autoantigen-specific circulating antibodies associated with neuropsychiatric morbidity and imaging features in patients with SLE.
Time Frame: 12 months (extensions allowed for existing MRI images before study onset)
|
High-throughput peptide and/or protein arrays customised according to the data derived from neuroimaging-annotated transcriptome analyses and/or from previous evidence from immune studies performed in a large multicentre cohort of patients with SLE (ZEUS study: NCT02403115) will be used to define candidate antigen targets for autoantibodies.
Serum samples will be collected longitudinally at time of clinical evaluation and neuroimaging and analysed by ELISA.
|
12 months (extensions allowed for existing MRI images before study onset)
|
|
To correlate antigen-specific CD4+ T-cell dynamics over time with the spectrum of SLE, NPSLE and associated MRI findings.
Time Frame: 12 months (extensions allowed for existing MRI images before study onset)
|
Major histocompatibility complex (MHC) multimers bound to relevant autoepitopes identified through in silico analyses of data from neuroimaging-annotated transcriptome analyses and/or from previous evidence from immune studies performed in a large multicentre cohort of patients with SLE (ZEUS study: NCT02403115) will be used to detect and track antigen-specific CD4+ T-cells.
Further characterisation of T-cells will be performed in terms of differentiation and polarisation.
In vitro T-cell reactivity assays with relevant autoepitopes will also be performed
|
12 months (extensions allowed for existing MRI images before study onset)
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- GR-2021-12372172
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.